Introduction
Globally, nearly 7 million people are coinfected with HIVand hepatitis C virus (HCV), representing about 20% of the HIV population [1] . In the United States and parts of Europe, coinfection prevalence among those with HIV is nearly 30%, with higher rates seen among clusters of high-risk groups such as intravenous drug users and MSM ESLD and HCC have become leading causes of mortality among the coinfected population in the era of combination antiretroviral therapy (cART) [15] . One cross-sectional study from France showed that death from liver disease contributed to nearly 25% of non-AIDSrelated deaths. Among those with ESLD, death due to HCC increased steadily over 10 years from 5 to 25% [16] . Compared with the general population, patients with coinfection are diagnosed at a younger age and are more than twice as likely to die of liver cancer [15, 17, 18] . Thus, reducing the risk of liver disease progression, cirrhosis, and HCC is of utmost importance in the HIV/HCV coinfected population.
Although successful treatment of HCV with direct-acting antivirals (DAAs) plays an important role in reducing the risk of ESLD, HCC, and mortality compared with those without [19] , cost and other barriers to therapy limit access to these medications for many patients. In addition, there is a residual risk for development of HCC after sustained viral response from DAAs for HCV in patients with cirrhosis [20] . Thus, utilizing other strategies to decrease the risk of ESLD and cirrhosis, including the use of medications that inhibit 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase (statins) as adjuncts in care for patients with chronic liver disease and HIV, is needed. Statins' pleotropic properties including their immunomodulatory, anti-inflammatory, and antineoplastic traits are thought to be beneficial in chronic disease states beyond their primary cardioprotective utility [21, 22] . Several studies of HCV monoinfected patients have also shown statins to be associated with reduced risk of cirrhosis and HCC [23] [24] [25] [26] . One study in veterans with diabetes suggested that statin medication may be useful in reducing the risk of developing HCC by 46% [95% confidence interval (CI) 0.55-0.75] [24] . To investigate the impact of statin medications and metabolic risk factors on liver progression among HIV/HCV coinfected individuals, we performed a retrospective study utilizing the Veterans Affairs HIV and HCV Clinical Case Registries (CCRs).
Methods

Data sources and patients
The study population consisted of HIV and HCV coinfected veterans whose health-related information was collected from the HIV and HCV Veterans Affairs CCR dating from 1 January 1999 to 31 December 2010. The CCRs are comprehensive databases extracted from the Veterans Affairs electronic medical record and include all laboratory, outpatient, inpatient, and pharmacy data on included patients [27] . The original cohort has been previously described in detail [12] . Figure 1 shows the additional restrictions made to the original cohort, which resulted in the final cohort used for these analyses. This study was approved by the Institutional Review Board of Baylor College of Medicine and Affiliated Institutions and the Michael E. DeBakey Veterans Affairs Medical Center Research and Development Committee.
Cirrhosis was defined by international classification of diseases (ICD)-9 codes for cirrhosis (571.2, 571.5, and 571.6) or aspartate aminotransferase-to-platelet ratio index greater than 2 (APRI score). A previous chart review validation study of the cirrhosis ICD-9 code showed that the positive predictive value compared with chart review was 90% [40] . Female veterans were also excluded because of small numbers (<2%). Patients lacking HCV RNA, follow-up CD4 þ cell count, or HIV viral load information were also excluded. Within the confirmed HIV/HCV coinfected cohort, patients with a diagnosis of cirrhosis prior to or within 90 days after the diagnosis of HIV or index date (1 January 1999) were excluded. Patients were censored at death, at the date of their last recorded healthcare encounter, or at the end of the study period.
Study variables
Metabolic risk factors were ascertained including degree of obesity, diabetes, hypertension, and low HDL. Diabetes was defined by hemoglobin A1c: glycalated hemoglobin measurement of at least 6.5% or ICD-9 codes 250.0-250.9, 357.2, 362.0, and 366.41. Hypertension was defined by ICD-9 codes 401.00-405.99. Low HDL was defined as HDL less than 40 mg/dl. Obesity was defined as BMI greater than 30 kg/m 2 . The maximum BMI was retained throughout the follow-up period. Alcohol use was defined as documented use of alcohol designated by the following ICD-9 codes: 571.0-571.3, 291, 303.0, 303.9, 305.0, and 535.3. Statin medication use was defined as percentage of follow-up time with an outpatient prescription for a statin drug prior to diagnosis of cirrhosis and was time-updated throughout the follow-up period. Prescriptions included rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, or lovastatin. Fig. 1 . Selection criteria for the final HIV/hepatitis C virus coinfected study cohort M . Ã Details of full cohort have previously been described [12] .
Other covariates defined at index date included age at HIV diagnosis, race, use of cART, and era of HIV diagnosis defined as pre-cART (<1996), early cART (1996) (1997) (1998) (1999) (2000) (2001) , and late cART (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) , and HCV genotype. Other HIV-specific variables included were CD4 þ cell count (cells/ml) most recent to event or censor and percentage of time with undetectable HIV viral load, both as time-updated variables throughout the study period. Comorbidities measured by Deyo Comorbidity score (excluding HIV) were also included in the multivariate analyses. All variables were time-dependent except age, race, era of HIV diagnosis, and HCV genotype. For time-varying covariates, missing data were excluded from the analysis until it became available later in the follow-up time, and then the last value was carried forward until a new value was available.
Data analysis
Primary outcome was time to cirrhosis. Descriptive analyses with chi-square and Fisher's exact tests were used to characterize and compare the demographic and disease characteristics of the noncirrhotic and cirrhotic groups. Cox proportional hazard regression analysis was used to calculate the effect of demographic, HIV-specific variables, metabolic variables, and statin drug use on time to cirrhosis. An interaction analysis between ALT and statin was performed, which led to stratification of patients on the basis of ALT above and below 40 IU/l. Log-rank test and Kaplan-Meier method were used to compare and demonstrate cumulative incidence of cirrhosis for patients group by ALT greater or less than 40 IU/l and percentage time on statin drug. SAS version 9.4 (SAS Institute Inc, Cary, North Carolina, USA) was used for all analyses. Cox proportional hazards regression was performed with SAS's PHREG procedure.
Results
The mean age among the final cohort (N ¼ 5985) was 45 years at the time of HIV diagnosis, and the mean followup time was 6.2 years. Of the total HIV/HCV coinfected cohort, 2265 developed cirrhosis by the end of follow-up, with crude incidence of cirrhosis of 6.1/100 personyears. The majority of patients in the cohort were black (66%) and were diagnosed with HIV during the fourth decade of life and in the early cART period (Table 1) . Initial APRI scores (median) were 0.6 and 0.47 (P < 0.0001) in the patients with and without cirrhosis, respectively. By the end of follow-up, the patients with cirrhosis had significantly higher APRI scores than patients without cirrhosis (2.23 versus 0.46, respectively, P < 0.0001). Eighty-three percent had received cART and had CD4 þ cell count values greater than 350 cells/ml (55%). Patients who developed cirrhosis were significantly less likely to receive cART (79.5%) and less likely to have CD4 þ cell count greater than 350 cells/ml (48.9%) compared with those without cirrhosis (85.7 and 59.2%, respectively). HIV viral load was suppressed in over 80% of the time; this was significantly less in the patients with cirrhosis compared with the patients without cirrhosis (19.8 versus 29%, P < 0.0001).
For the metabolic risk factors, over one-fifth of the total cohort was obese on the basis of BMI greater than 30 kg/m 2 . Diabetes was present in about 16% of the total group and was not significantly different between the patients with and without cirrhosis. Over 50% of the cohort had hypertension and low HDL, and these features were more prevalent in the patients without cirrhosis compared with those with cirrhosis (60 and 64% compared with 45.6 and 55.6%, respectively). Initial LDL in patients with cirrhosis was 91.2 mg/dl, and at last follow-up it was 84.4 mg/dl. In patients without cirrhosis, index LDL and last follow-up LDL were 94.4 and 89.4 mg/dl, respectively. Few patients had ever been prescribed statin medications, and prescriptions were significantly lower in the cirrhotic group compared with noncirrhotic (8 and 20.6%, respectively). Among all patients, statins were prescribed in 12.5 and 21.2% of patients with and without cirrhosis, respectively (P ¼ 0.0001). Figure 2 demonstrates patient groups stratified by ALT value and percentage time on statin. For patients with ALT 40 IU/l or less, statin use greater or equal to 30% time was significantly associated with reduced risk of development of cirrhosis compared with those with less time on statin drugs. Likewise, for patients with ALT greater than 40 IU/l, patients with more than 30% time on statin was also significantly protective for cirrhosis development compared with those with less time on statin drugs.
In preliminary multivariate analyses, an interaction between ALT and statin use was statistically significant (Supplemental Table 1 , http://links.lww.com/QAD/ A965). Thus, further multivariate analyses were stratified by ALT level to minimize the effect of modification bias of ALT on statin use in the multivariate analyses. In the ALT 40 IU/l or less group, every 1% time on statin was associated with a decreased risk of cirrhosis [adjusted hazard ratio (aHR), 0.98, 95% CI 0.97-0.99]. This translates to a 32% (aHR 0.68, 95% CI 0.47-0.98) reduction in progression to cirrhosis for individuals with at least 30% time on statins ( Table 2 ). For patients with ALT greater than 40 IU/l levels, each 1% of time on statins was associated with a nonsignificant decreased risk of cirrhosis (aHR 0.95, 95% CI 0.9-1). To adjust for the competing risk of death, we performed a sensitivity analysis using multivariate hazard regression models excluding patients who died before the diagnosis of cirrhosis or censor. After excluding patients who died before cirrhosis or censor date, we found that every 30% of time on statin was still associated with a significant 35% reduction in cirrhosis progression (95% CI 0.45-0.95). In the ALT 40 IU/l or less group, other metabolic risk factors including diabetes, low HDL, and hypertension were harmful, but did not significantly impact progression to cirrhosis. Within the ALT greater than 40 IU/l group, diabetes and low HDL were consistently associated with an increased risk of cirrhosis (aHR 1.15, 95% CI 1.01-1.31 and aHR 1.3, 95% CI 1.2-1.44), respectively. Hypertension was associated with a greater risk of cirrhosis in both groups, but it was not significant.
Obesity was found to have a protective effect in both groups, but was only significant in those with ALT greater than 40 IU/l (aHR 0.85, 95% CI 0.76-0.95).
Several demographic and HIV-specific covariates were significantly related to cirrhosis incidence. Patients over 50 years old with ALT 40 IU/l or less were at higher risk for cirrhosis (aHR 2.5, 95% CI 1.54-4.18). Patients with Deyo comorbidity score of greater than 1 in the ALT 40 IU/l or less group also increased the risk cirrhosis (aHR 3.23, 95% CI 2.3-4.5). Alcohol use was significantly associated with liver disease progression only in patients with ALT greater than 40 IU/l (aHR Follow-up in years after index date ALT > 40 IU/l P < 0.0001
ALT ≤ 40 IU/l P < 0.0001 Fig. 2 . Kaplan-Meier cumulative cirrhosis incidence among HIV/hepatitis C virus coinfected patients as stratified by alanine aminotransferase groups and between those with more or less than 30% time with statin medication. , statin <30% time;
, statin !30% time. 1.15, 95% CI 1.04-1.26). Poor immunological control with CD4 þ cell count less than 200 cells/ml conferred greatest risk of cirrhosis in both ALT 40 IU/l or less and greater than 40 IU/l groups (aHR 2.4, 95% CI 1.8-3.2 and aHR 1.9, 95% 1.71-2.12), respectively. Those patients with greater than 80% time with an undetectable HIV viral load in both ALT 40 IU/l or less and greater than 40 IU/l groups had a significantly lower risk of cirrhosis (aHR 0.72, 95% CI 0.5-1.0, aHR 0.72, 95% CI 0.64-0.8), respectively.
Discussion
To our knowledge, this is the largest study of HIV/HCV coinfected individuals to examine the effect of statin drugs on cirrhosis development. Furthermore, in contrast to previous studies, the current study specifically adjusts for confounding by indication of nonstatin receipt due to elevated ALT during follow-up years. We have demonstrated that statin drug use in patients with HIV/HCV coinfection and normal liver function decreased the risk of cirrhosis, particularly among those with ALT 40 IU/l or less. Among patients with ALT greater than 40 IU/l, metabolic risk factors including low HDL and diabetes also were significantly associated with development of cirrhosis.
Statin therapy in HCV monoinfection has been shown in two recent studies from the United States (small, prospective) and Taiwan (large, retrospective) to reduce the cirrhosis risk by 69 and 87%, respectively [25, 26] .
Although the study conducted in Taiwan did not adjust for ALT variation within the study participants, it demonstrated both dose and time-dependent effects in the development of cirrhosis. This may be due in part to better regulation of the proinflammatory mechanisms and oxidative stress seen in chronic HCV. Alternately, statins may have a more direct role interfering with the ability of HCV to harness the host lipid metabolism in its replication mechanisms [28] .
Other metabolic risk factors demonstrated significant associations with the development of cirrhosis for patients with elevated ALT in our study. The development of metabolic derangements is common in patients with chronic HCV and can be seen in over 50% of this population, making this population at high risk for a proinflammatory and high oxidative stress environment [29] . In addition, many of these metabolic risk factors such as diabetes and lipid derangements with liver fibrosis are associated with NAFLD progression, another growing problem in the HIV-infected population [14] [15] [16] [17] [18] [19] . Although we did not find a protective effect of statins on those with ALT greater than 40 IU/l, statin medications may improve low HDL, a manifestation of lipid dysregulation in chronic HCV, as well as improve anti-inflammatory and antiproliferative effects.
Diabetes has been shown to increase the risk of HCC in HCV monoinfected individuals [30] . Diabetes control is also a modifiable risk factor and can be targeted as a therapeutic strategy to reduce oxidative stress and decrease the risk of fibrosis progression. Only few studies have examined the role of antidiabetic agents in NAFLD; however, there is substantial promise for these agents, especially the thializodinediones, in mitigating risk of liver fibrosis [31] . The benefit of antidiabetes medications in HCV/HIV coinfection is less clearly understood and represents an area of further research.
As in previous studies of HIV/HCV coinfected individuals, we found that host-related factors, such as older age at diagnosis of HIV, greater comorbidities, and low CD4 þ cell count, were significantly linked to liver fibrosis development in our cohort for ALT groups below and above 40 IU/l [8, 32, 33] . We also found that patients who had a higher percentage time with undetectable viral load during follow-up decreased risk of cirrhosis development [13, 34] . HIV treatment with cART and adherence to therapy are known to play critical roles in reducing risk of liver disease progression and ultimately decompensation. Patients with cirrhosis received less cART, which may have multifactorial reasons including adherence, poor social support, as well as provider hesitation. Our results, however, demonstrate that above and beyond other known factors related to greater immunologic control and viral suppression known to be associated with reduced risk of liver fibrosis and slower progression in HIV/HCV coinfection, statin use additionally decreases cirrhosis risk [13, 35, 36] .
Unsurprisingly, we found that our cohort of chronic liver disease patients received few statin prescriptions, particularly among patients with ALT greater than 40 IU/l. This phenomenon is likely due to provider hesitation in prescribing medications with potential hepatotoxicity [37] . Statin medication use in the presence of liver disease or enzyme elevation is generally safe and well tolerated [38, 39] , and if followed closely, patients with slightly elevated ALT should be able to receive statins. Our finding that statins are beneficial in reducing progression to cirrhosis adds to the growing body of evidence of the beneficial use of statins beyond its utility in cardiovascular disease, and they should be considered in patients even with chronic liver disease.
Study limitations include the following: the study was a retrospective cohort study using data extracted by ICD-9 codes, lab values, and pharmacy records from medical care records; however, many of these variables have been validated in other Veterans Affairs studies [40] . Specifically, alcohol utilization may not be completely captured with ICD-9 codes. Outside claims data including Medicare and fee-based sources were not included in the analyses because they are not included in the CCR. In addition, prescribing practices among different providers and varying cART regimens may have affected frequency and dosage of statin drug use. However, we attempted to address this limitation by carefully identifying the cohort and adjusting for cART use and stratifying by ALT to minimize confounding. Because we had so few patients on statins in the ALT greater than 40 patients, our analyses of individuals with more advanced cirrhosis and high ALT are limited and should be interpreted with caution. In addition, patients with prolonged chronic hepatitis may have had abnormal lipid profiles with low total cholesterol and low LDL [28] , which may have led to less statin receipt for hyperlipidemia; however, we adjusted for lipid values in the multivariable analyses. In addition, although we were unable to conduct classic competing risk analyses for death due to use of time-dependent variables in the Cox model, in our sensitivity analysis of excluding individuals who died prior to the cirrhosis diagnosis or censor from the cohort, we continued to find a significant protective effect from statin use. Finally, generalizability may also be limited as our study included only male patients, and the majority were over 40 years old at time of HIV diagnosis. In conclusion, this study demonstrated that statin use in an HIV/HCV coinfected population with minimal liver dysfunction was associated with reduced risk of progression to advanced liver disease. Until effective therapies for treating HCV become widely available, statin use may be an important, cost-effective adjunct in the care of HIV/HCV coinfected patients. We also found that metabolic risk factors such as low HDL and diabetes are associated with development of cirrhosis. It is possible that treatment of these comorbidities could also help mitigate hepatic decompensation. Further prospective studies are needed to better understand the safety and efficacy of statin use in the prevention of cirrhosis and HCC.
Keypoints: Statin drugs may be a useful adjunct in mitigating risk of cirrhosis in patients with chronic liver disease, but normal liver function. Metabolic risk factors including low HDL and diabetes are also associated with liver disease progression. Older age, more comorbidities, and poorer HIV control are associated with cirrhosis development.
